JP2017523776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523776A5 JP2017523776A5 JP2017502121A JP2017502121A JP2017523776A5 JP 2017523776 A5 JP2017523776 A5 JP 2017523776A5 JP 2017502121 A JP2017502121 A JP 2017502121A JP 2017502121 A JP2017502121 A JP 2017502121A JP 2017523776 A5 JP2017523776 A5 JP 2017523776A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- gene
- expression
- rpl13a
- ets1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 51
- 108090000623 proteins and genes Proteins 0.000 claims 44
- 238000000034 method Methods 0.000 claims 43
- 239000005557 antagonist Substances 0.000 claims 27
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 26
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 26
- 102100022289 60S ribosomal protein L13a Human genes 0.000 claims 19
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 claims 19
- -1 MBP Proteins 0.000 claims 19
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims 18
- 102100035251 Protein C-ets-1 Human genes 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 18
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 17
- 101150008012 Bcl2l1 gene Proteins 0.000 claims 17
- 102000049320 CD36 Human genes 0.000 claims 17
- 108010045374 CD36 Antigens Proteins 0.000 claims 17
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims 17
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 17
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims 17
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims 17
- 102100033461 Interleukin-17A Human genes 0.000 claims 17
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 17
- 108700000711 bcl-X Proteins 0.000 claims 17
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 claims 16
- 102000009069 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Human genes 0.000 claims 16
- 102100026882 Alpha-synuclein Human genes 0.000 claims 16
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims 16
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims 16
- 102100021179 Dynamin-3 Human genes 0.000 claims 16
- 102100040565 Dynein light chain 1, cytoplasmic Human genes 0.000 claims 16
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 16
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 16
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 16
- 101000817599 Homo sapiens Dynamin-3 Proteins 0.000 claims 16
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 claims 16
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 16
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 16
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 16
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 claims 16
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims 16
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 16
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims 16
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 16
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 16
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 16
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 16
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 16
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims 16
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 claims 16
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 16
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 16
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 16
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims 16
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 claims 15
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 claims 15
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 claims 15
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 claims 15
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 claims 15
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 claims 15
- 238000011282 treatment Methods 0.000 claims 15
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 14
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 14
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims 13
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 208000005017 glioblastoma Diseases 0.000 claims 12
- 239000013610 patient sample Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102220473068 Chemerin-like receptor 2_R17Q_mutation Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000018899 proneural glioblastoma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024244P | 2014-07-14 | 2014-07-14 | |
| US62/024,244 | 2014-07-14 | ||
| PCT/US2015/040408 WO2016011052A1 (en) | 2014-07-14 | 2015-07-14 | Diagnostic methods and compositions for treatment of glioblastoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523776A JP2017523776A (ja) | 2017-08-24 |
| JP2017523776A5 true JP2017523776A5 (OSRAM) | 2018-08-30 |
Family
ID=53762365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502121A Pending JP2017523776A (ja) | 2014-07-14 | 2015-07-14 | 膠芽腫の診断方法及びその治療用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10208355B2 (OSRAM) |
| EP (1) | EP3169801A1 (OSRAM) |
| JP (1) | JP2017523776A (OSRAM) |
| CN (1) | CN106460067A (OSRAM) |
| WO (1) | WO2016011052A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN110023762A (zh) * | 2016-12-01 | 2019-07-16 | 参天制药株式会社 | 用于预测利用抗vegf药物对渗出性年龄相关性黄斑变性进行的处置的有效性的方法 |
| CN108728533B (zh) * | 2017-04-20 | 2022-06-14 | 常青 | 用于髓母细胞瘤分子分型的基因群以及snca基因作为4型髓母细胞瘤的生物标志物的用途 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| EP3893902B1 (en) | 2018-12-11 | 2024-10-23 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of pd-l1 activity or expression for use in the treatment of serrated colorectal cancer |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| DE102020004924A1 (de) * | 2020-08-13 | 2022-02-17 | Daimler Ag | Bodenstruktur für eine Karosserie eines Fahrzeugs, Karosserie für ein Fahrzeug sowie Fahrzeug |
| KR102878653B1 (ko) * | 2022-04-08 | 2025-10-31 | 연세대학교 산학협력단 | 유전자로 정의된 암기원세포, 및 이의 분류방법 |
| KR102878656B1 (ko) * | 2022-04-08 | 2025-10-31 | 연세대학교 산학협력단 | 유전자로 정의된 암기원세포, 및 이의 분류방법 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| SI1695985T1 (sl) | 1997-04-07 | 2011-06-30 | Genentech Inc | Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP2003529774A (ja) | 2000-03-31 | 2003-10-07 | ジェネンテック・インコーポレーテッド | 遺伝子発現を検出し定量するための構成物及び方法 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| JP4599355B2 (ja) | 2003-07-28 | 2010-12-15 | ジェネンテック， インコーポレイテッド | プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減 |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CN101336300A (zh) * | 2005-12-16 | 2008-12-31 | 健泰科生物技术公司 | 神经胶质瘤的诊断、预后和治疗方法 |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| CA2679943A1 (en) | 2007-03-02 | 2008-09-12 | Board Of Regents, The University Of Texas System | Multigene assay to predict outcome in an individual with glioblastoma |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| SG175289A1 (en) | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
| KR20120059553A (ko) * | 2009-08-14 | 2012-06-08 | 제넨테크, 인크. | Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커 |
| MX2012009554A (es) | 2010-02-23 | 2012-11-23 | Hoffmann La Roche | Terapia anti-angiogenesis para el tratamiento del cancer ovarico. |
| AU2011293522B2 (en) | 2010-08-24 | 2015-03-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| BR112014017320A2 (pt) | 2012-01-13 | 2018-05-29 | Genentech Inc | método para determinar se um paciente é propenso a responder ao tratamento com um antagonista de vegf, método para otimizar a eficácia terapêutica de um antagonista de vegf, método para selecionar uma terapia, método para identificar um biomarcador e método para diagnosticar um distúrbio angiogênico |
| KR20140142719A (ko) * | 2012-03-30 | 2014-12-12 | 제넨테크, 인크. | 암의 치료를 위한 진단 방법 및 조성물 |
| GB201207722D0 (en) * | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| CN104507498A (zh) | 2012-08-07 | 2015-04-08 | 霍夫曼-拉罗奇有限公司 | 用于治疗成胶质细胞瘤的组合疗法 |
| AU2013353839A1 (en) * | 2012-12-03 | 2015-06-18 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
-
2015
- 2015-07-14 JP JP2017502121A patent/JP2017523776A/ja active Pending
- 2015-07-14 EP EP15744808.5A patent/EP3169801A1/en not_active Withdrawn
- 2015-07-14 WO PCT/US2015/040408 patent/WO2016011052A1/en not_active Ceased
- 2015-07-14 CN CN201580031397.3A patent/CN106460067A/zh active Pending
-
2016
- 2016-11-08 US US15/346,164 patent/US10208355B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523776A5 (OSRAM) | ||
| TWI851580B (zh) | 對nectin-4具有專一性之雙環胜肽配體 | |
| Hamid et al. | Intratumoral immunotherapy—update 2019 | |
| Chen et al. | Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes | |
| Wick et al. | Current status and future directions of anti-angiogenic therapy for gliomas | |
| JP6857498B2 (ja) | 癌を処置するための併用方法 | |
| Sheahan et al. | Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review | |
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| JP2015512612A5 (OSRAM) | ||
| Tezuka et al. | Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells | |
| Sevastre et al. | Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments | |
| Haddad et al. | Using viral vectors to deliver local immunotherapy to glioblastoma | |
| JP6337258B2 (ja) | 腫瘍免疫又は感染免疫を増強させる免疫増強剤 | |
| Narayanan et al. | Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID | |
| US20240408071A1 (en) | Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer | |
| TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| Yin et al. | PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer | |
| CA2824417C (en) | Mycobacterium w for use in treating cancer | |
| Sun et al. | 1320TiP The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study | |
| Steendam et al. | Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma | |
| CN110494137A (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 | |
| Moon et al. | An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1 | |
| MM et al. | Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers | |
| Lisberg et al. | 1199TiP Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC | |
| TW202002952A (zh) | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |